OA10375A - Interleukin-15 - Google Patents

Interleukin-15 Download PDF

Info

Publication number
OA10375A
OA10375A OA60897A OA60897A OA10375A OA 10375 A OA10375 A OA 10375A OA 60897 A OA60897 A OA 60897A OA 60897 A OA60897 A OA 60897A OA 10375 A OA10375 A OA 10375A
Authority
OA
OAPI
Prior art keywords
polypeptide
host cell
dna
leu
ser
Prior art date
Application number
OA60897A
Other languages
English (en)
Inventor
Kenneth H Grabstein
Dirk M Anderson
June R Eisenman
Charles Rauch
Victor Fung
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PT94915781T priority Critical patent/PT772624E/pt
Priority to DK94915781T priority patent/DK0772624T3/da
Priority to EP94915781A priority patent/EP0772624B1/fr
Priority to PCT/US1994/003793 priority patent/WO1995027722A1/fr
Priority to CA002186747A priority patent/CA2186747C/fr
Priority to AT94915781T priority patent/ATE196315T1/de
Priority to JP7526299A priority patent/JPH09512165A/ja
Priority to AU67673/94A priority patent/AU680909B2/en
Priority to NZ266264A priority patent/NZ266264A/en
Priority to DE69425906T priority patent/DE69425906T2/de
Priority to ES94915781T priority patent/ES2151927T3/es
Priority claimed from ZA942636A external-priority patent/ZA942636B/xx
Priority to ZA942636A priority patent/ZA942636B/xx
Priority to FI963828A priority patent/FI117054B/fi
Priority to OA60897A priority patent/OA10375A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Priority to NO19964141A priority patent/NO318435B1/no
Priority to GR20000402710T priority patent/GR3035019T3/el
Publication of OA10375A publication Critical patent/OA10375A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
OA60897A 1994-04-06 1996-09-27 Interleukin-15 OA10375A (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DE69425906T DE69425906T2 (de) 1994-04-06 1994-04-06 Interleukin-15
NZ266264A NZ266264A (en) 1994-04-06 1994-04-06 Mammalian epithelium-derived t-cell factor called interleukin-15
PCT/US1994/003793 WO1995027722A1 (fr) 1994-04-06 1994-04-06 Interleukine-15
CA002186747A CA2186747C (fr) 1994-04-06 1994-04-06 Interleukine-15
AT94915781T ATE196315T1 (de) 1994-04-06 1994-04-06 Interleukin-15
JP7526299A JPH09512165A (ja) 1994-04-06 1994-04-06 インターロイキン１５
AU67673/94A AU680909B2 (en) 1994-04-06 1994-04-06 Interleukin-15
PT94915781T PT772624E (pt) 1994-04-06 1994-04-06 Interleucina-15
EP94915781A EP0772624B1 (fr) 1994-04-06 1994-04-06 Interleukine-15
DK94915781T DK0772624T3 (da) 1994-04-06 1994-04-06 Interleukin-15
ES94915781T ES2151927T3 (es) 1994-04-06 1994-04-06 Interleuquina-15.
ZA942636A ZA942636B (en) 1994-04-06 1994-04-18 Interleukin-15
FI963828A FI117054B (fi) 1994-04-06 1996-09-25 Interleukiini-15:n valmistusmenetelmä ja sitä koodaava DNA-sekvenssi
OA60897A OA10375A (en) 1994-04-06 1996-09-27 Interleukin-15
NO19964141A NO318435B1 (no) 1994-04-06 1996-09-30 Isolert DNA-sekvens fra IL-15, isolert DNA-sekvens som koder for et forloperpolypeptid til det biologisk aktive IL-15 polypeptid, rekombinant ekspresjonsvektor, vertcelle, fremgangsmate for fremstilling av et IL-15 polypeptid, isolert biologisk aktivt IL-15 polypeptidpreparat, farmasoytisk preparat for stimmulering av proliferasjon av T-lymfocytter, samt anvendelse av et polypeptid ifolge oppfinnelsen for fremstilling av et middel for behandling eller forebyggelse av spesifikt angitte sykdommer.
GR20000402710T GR3035019T3 (en) 1994-04-06 2000-12-06 Interleukin-15

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NZ266264A NZ266264A (en) 1994-04-06 1994-04-06 Mammalian epithelium-derived t-cell factor called interleukin-15
PCT/US1994/003793 WO1995027722A1 (fr) 1994-04-06 1994-04-06 Interleukine-15
ZA942636A ZA942636B (en) 1994-04-06 1994-04-18 Interleukin-15
OA60897A OA10375A (en) 1994-04-06 1996-09-27 Interleukin-15

Publications (1)

Publication Number Publication Date
OA10375A true OA10375A (en) 2001-11-16

Family

ID=33314371

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60897A OA10375A (en) 1994-04-06 1996-09-27 Interleukin-15

Country Status (11)

Country Link
EP (1) EP0772624B1 (fr)
AT (1) ATE196315T1 (fr)
CA (1) CA2186747C (fr)
DE (1) DE69425906T2 (fr)
DK (1) DK0772624T3 (fr)
ES (1) ES2151927T3 (fr)
GR (1) GR3035019T3 (fr)
NZ (1) NZ266264A (fr)
OA (1) OA10375A (fr)
PT (1) PT772624E (fr)
WO (1) WO1995027722A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0823257B1 (fr) * 1995-04-02 2002-08-07 Chugai Seiyaku Kabushiki Kaisha Composition medicinale pour guerir la thrombopenie
JP4128625B2 (ja) 1995-10-17 2008-07-30 ウェイン ステイト ユニヴァーシティ チキンインターロイキン−１５及びその使用
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
CA2252557A1 (fr) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center, Inc. Antagonistes de l'interleukine-15
EP1627918A1 (fr) * 1996-04-26 2006-02-22 Beth Israel Deaconess Medical Center, Inc. Antagonistes de l'interleukine-15
US6087172A (en) * 1997-10-31 2000-07-11 Hisamitsu Pharmaceutical Co., Inc. Ribozymes targeted to human IL-15 mRNA
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
WO2000050569A1 (fr) * 1999-02-24 2000-08-31 The Wistar Institute Of Anatomy And Biology Procede de modification pour cellules cytotoxiques et utilisations correspondantes
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
WO2001087330A2 (fr) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions et procedes pour obtenir une suppression immune
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
CN100427597C (zh) * 2003-11-26 2008-10-22 中国医学科学院基础医学研究所 可用于生产人重组白细胞介素-15的原核表达工程菌及纯化方法
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
ES2382775T3 (es) * 2004-10-08 2012-06-13 Government Of The United States Of America,As Represented By The Secretary, Department Of Health And Human Services Inmunoterapia adoptiva con supervivencia de linfocitos T potenciada.
JP5236461B2 (ja) 2005-05-17 2013-07-17 ユニバーシティ オブ コネチカット 生物におけるイムノモデュレーションのための組成物および方法
EP1777294A1 (fr) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
WO2007084342A2 (fr) 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Il-15 et il-15r-alpha améliorées aux fins d'expression dans des cellules mammaliennes
CA3028038C (fr) 2007-05-11 2021-08-10 Altor Bioscience Corporation Molecules de fusion et variants d'il-15
ES2466916T3 (es) 2007-06-27 2014-06-11 Admune Therapeutics Llc Complejos de IL-15 e IL-15R alfa y usos de los mismos
WO2009135031A1 (fr) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Il-15 substitué
AU2010282280B2 (en) 2009-08-14 2016-06-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 to increase thymic output and to treat lymphopenia
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
CA2811734C (fr) 2010-09-21 2021-11-23 Altor Bioscience Corporation Molecules de fusion multimeres solubles a base d'il-15, leurs procedes de preparation et d'utilisation
EP2537933A1 (fr) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
EP2791322A1 (fr) 2011-12-12 2014-10-22 Cell Medica Limited Procédé de propagation de cellules t
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
KR20150145260A (ko) 2013-04-19 2015-12-29 싸이튠 파마 감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료
EP2915569A1 (fr) 2014-03-03 2015-09-09 Cytune Pharma Procédé de purification de conjugués à base Il -15/IL-15Ralpha
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
KR102503476B1 (ko) 2014-06-30 2023-02-24 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
CA2998649A1 (fr) 2015-09-18 2017-03-23 Baylor College Of Medicine Identification d'antigene immunogene a partir d'un pathogene et correlation avec l'efficacite clinique
CA3029813A1 (fr) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methodes et procedes pour favoriser la fonction des cellules immunitaires
KR20190091264A (ko) 2016-10-21 2019-08-05 알토 바이오사이언스 코포레이션 다량체 il-15 기반 분자
CA3059634A1 (fr) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Immunotherapie anticancereuse combinatoire
US12036283B2 (en) 2017-05-15 2024-07-16 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
KR102008429B1 (ko) 2017-06-30 2019-08-07 아주대학교산학협력단 인터루킨-15/인터루킨-15 수용체 알파-Fc 복합체를 포함하는 염증질환 치료 또는 예방용 조성물
EP3678701A4 (fr) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. Compositions protéiques thérapeutiques et procédés de préparation et d'utilisation de celles-ci
SG11202103317XA (en) 2018-10-17 2021-05-28 Senti Biosciences Inc Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN116981685A (zh) * 2020-12-03 2023-10-31 世纪治疗股份有限公司 基因工程化细胞及其用途
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (fr) 2022-11-07 2024-05-16 Xencor, Inc. Anticorps bispécifiques qui se lient à b7h3 et mica/b

Also Published As

Publication number Publication date
PT772624E (pt) 2001-03-30
NZ266264A (en) 1997-01-29
EP0772624B1 (fr) 2000-09-13
DE69425906T2 (de) 2001-03-29
WO1995027722A1 (fr) 1995-10-19
EP0772624A1 (fr) 1997-05-14
DK0772624T3 (da) 2000-11-13
ATE196315T1 (de) 2000-09-15
EP0772624A4 (fr) 1997-07-02
DE69425906D1 (en) 2000-10-19
ES2151927T3 (es) 2001-01-16
CA2186747C (fr) 2009-01-27
GR3035019T3 (en) 2001-03-30
CA2186747A1 (fr) 1995-10-19

Similar Documents

Publication Publication Date Title
OA10375A (en) Interleukin-15
US5552303A (en) DNA encoding epithelium-derived T-cell factor
US5985262A (en) Method of treatment with epithelium derived T-cell factor
US7875709B2 (en) Nucleic acids encoding interleukin-18 mutants
EP0991661B1 (fr) Proteine chimere du recepteur d'interleukine-6 soluble/ligand, analogues de celle-ci et applications
JP4276783B2 (ja) Ｉｌ−２の選択的アゴニスト及びアンタゴニスト
AU2002324249A1 (en) Interleukin-18 mutants, their production and use
AU680909B2 (en) Interleukin-15
EP0335900A1 (fr) Muteines d'interleukine-4 humaine
US7625553B2 (en) Method of treating cancer by administering an epithelum-derived T-cell factor
JP3689111B2 (ja) インターロイキン１５